Director/PDMR Shareholding

12 Nov 2007 10:35

Vernalis PLC12 November 2007 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS VERNALIS PLC WINNERSH, UK 12th November 2007 - Vernalis plc (LSE : VER) ("Vernalis" or the"Company") announces that it has been informed that Dr Peter Fellner, ExecutiveChairman of the Company, on 9th November 2007, bought 110,000 Ordinary 5 penceshares (0.035% of the current issued share capital) at a price of 13.25 penceper share. Following this purchase of shares, Dr Fellner is the beneficial owner of 525,888Ordinary 5 pence shares, representing 0.168% of the Company's current issuedshare capital. About Vernalis Vernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, FROVA(R) andApokyn(R), and a development pipeline focused on central nervous systemdisorders. The company has eight products in registration/clinical developmentand collaborations with leading, global pharmaceutical companies includingNovartis, Biogen Idec, Servier, Chiesi and Serono. Vernalis has established aU.S. commercial operation to promote Apokyn(R) and co-promote FROVA(R) alongsideits North American licensing partner, Endo Pharmaceuticals, progressing thecompany towards its goal of becoming a sustainable, self-funding, R&D-driven,speciality bio-pharmaceutical company. For further information about Vernalis,please visit: www.vernalis.com Vernalis plc +44 (0) 118 977 3133 Simon Sturge, Chief Executive Officer Tony Weir, Chief Financial Officer Brunswick Group +44 (0) 20 7404 5959 Jon Coles Justine Mcilroy Alex Tweed This information is provided by RNS The company news service from the London Stock Exchange